We have updated recommendations on 12 controversial topics that were published in the
2013 National Consensus on the diagnosis, risk stratification and treatment of patients with …

In cancer patients, pulmonary embolism (PE) is the second leading cause of death after the
cancer itself, most likely because of difficulties in diagnosing the disease due to its …

Importance The optimal treatment of intermediate-high–risk pulmonary embolism (PE)
remains unknown. Objective To assess the effect of conventional catheter-directed …

Background Improved prediction of the risk of early major bleeding in pulmonary embolism
(PE) is needed to optimize acute management. Research Question Does a simple scoring …

Acute pulmonary embolism (PE) is associated with significant morbidity and mortality. The
management paradigm for acute PE has evolved in recent years with wider availability of …

Approximately 5% of pulmonary embolism (PE) cases present with persistent hypotension,
obstructive shock, or cardiac arrest. Given the high short-term mortality, management of high …

Pulmonary embolism (PE) is the third-leading cause of cardiovascular mortality and the
second-leading cause of death in cancer patients. The clinical efficacy of thrombolysis for …

Simple Summary Patients with venous thromboembolism events in the context of cancer
should receive anticoagulants as long as the cancer is active. Therefore, a tailor-made …

Background Dissecting trends and contributing risk factors for intracranial hemorrhage (ICH)
in patients treated for acute pulmonary embolism (PE) may allow for a better patient …

Background Renal dysfunction influences outcomes after pulmonary embolism (PE). We
aimed to determine the incremental value of adding renal dysfunction, defined by estimated …